Clinical Trial Update: Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating autologous muscle-derived cells for tongue-related dysphagia (AMDC-GIR) is listed as active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oropharyngeal Dysphagia

Drugs mentioned

• Autologous Muscle Derived Cells (AMDC-GIR)

Snippet

Sponsor: Peter Belafsky, MD | Conditions: Oropharyngeal Dysphagia | Phase 1 | Status: ACTIVE_NOT_RECRUITING